Thomas Malley - Net Worth and Insider Trading
Thomas Malley Net Worth
The estimated net worth of Thomas Malley is at least $8 Million dollars as of 2024-11-29. Thomas Malley is the Director of BeiGene Ltd and owns about 30,000 shares of BeiGene Ltd (BGNE) stock worth over $6 Million. Thomas Malley is the Director of Kura Oncology Inc and owns about 139,557 shares of Kura Oncology Inc (KURA) stock worth over $2 Million. Thomas Malley is also the Director of Puma Biotechnology Inc and owns about 156,551 shares of Puma Biotechnology Inc (PBYI) stock worth over $505,660. Besides these, Thomas Malley also holds Millendo Therapeutics Inc (MLND) . Details can be seen in Thomas Malley's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas Malley has not made any transactions after 2023-06-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas Malley
Thomas Malley Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Malley owns 6 companies in total, including Kiniksa Pharmaceuticals International PLC (KNSA) , Kura Oncology Inc (KURA) , and BeiGene Ltd (BGNE) among others .
Click here to see the complete history of Thomas Malley’s form 4 insider trades.
Insider Ownership Summary of Thomas Malley
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International PLC | 2018-05-23 | director |
| KURA | Kura Oncology Inc | 2023-06-16 | director |
| BGNE | BeiGene Ltd | 2016-11-23 | director |
 | | 2017-06-13 | director |
| | 2012-10-24 | director |
| | 2013-06-07 | director |
Thomas Malley Latest Holdings Summary
Thomas Malley currently owns a total of 4 stocks. Among these stocks, Thomas Malley owns 30,000 shares of BeiGene Ltd (BGNE) as of November 23, 2016, with a value of $6 Million and a weighting of 74.97%. Thomas Malley owns 139,557 shares of Kura Oncology Inc (KURA) as of June 16, 2023, with a value of $2 Million and a weighting of 18.9%. Thomas Malley also owns 156,551 shares of Puma Biotechnology Inc (PBYI) as of October 24, 2012, with a value of $505,660 and a weighting of 6.13%. The other 1 stocks Millendo Therapeutics Inc (MLND) have a combined weighting of 0.01% among all his current holdings.
Latest Holdings of Thomas Malley
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BGNE | BeiGene Ltd | 2016-11-23 | 30,000 | 206.16 | 6,184,800 |
| KURA | Kura Oncology Inc | 2023-06-16 | 139,557 | 11.17 | 1,558,852 |
| PBYI | Puma Biotechnology Inc | 2012-10-24 | 156,551 | 3.23 | 505,660 |
| MLND | Millendo Therapeutics Inc | 2015-04-08 | 543 | 1.06 | 576 |
Holding Weightings of Thomas Malley
Thomas Malley Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Malley has made a total of 0 transactions in BeiGene Ltd (BGNE) over the past 5 years. The most-recent trade in BeiGene Ltd is the acquisition of 30,000 shares on November 23, 2016, which cost Thomas Malley around $960,000.
According to the SEC Form 4 filings, Thomas Malley has made a total of 1 transactions in Kura Oncology Inc (KURA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Kura Oncology Inc is the acquisition of 50,000 shares on June 16, 2023, which cost Thomas Malley around $575,000.
According to the SEC Form 4 filings, Thomas Malley has made a total of 0 transactions in Puma Biotechnology Inc (PBYI) over the past 5 years. The most-recent trade in Puma Biotechnology Inc is the acquisition of 10,000 shares on October 24, 2012, which cost Thomas Malley around $160,000.
More details on Thomas Malley's insider transactions can be found in the Insider Trading History of Thomas Malley table.Insider Trading History of Thomas Malley
- 1
Thomas Malley Trading Performance
GuruFocus tracks the stock performance after each of Thomas Malley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Malley is -0.53%. GuruFocus also compares Thomas Malley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Malley within 3 months outperforms 4 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas Malley's insider trading performs compared to the benchmark.
Performance of Thomas Malley
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -8.68 | | | | | |
| Relative Return to S&P 500(%) | -10.07 | | | | | |
Thomas Malley Ownership Network
Thomas Malley Owned Company Details
What does Kiniksa Pharmaceuticals International PLC do?
Who are the key executives at Kiniksa Pharmaceuticals International PLC?
Thomas Malley is the director of Kiniksa Pharmaceuticals International PLC. Other key executives at Kiniksa Pharmaceuticals International PLC include Chief Business Officer Eben Tessari , director & 10 percent owner & Chairman & CEO Sanj K Patel , and Group VP & Rilonacept GM Ross Moat .
Kiniksa Pharmaceuticals International PLC (KNSA) Insider Trades Summary
Over the past 18 months, Thomas Malley made no insider transaction in Kiniksa Pharmaceuticals International PLC (KNSA). Other recent insider transactions involving Kiniksa Pharmaceuticals International PLC (KNSA) include a net sale of 150,848 shares made by John Paolini , a net sale of 309,021 shares made by Sanj K Patel , and a net sale of 69,000 shares made by Eben Tessari .
In summary, during the past 3 months, insiders sold 270,259 shares of Kiniksa Pharmaceuticals International PLC (KNSA) in total and bought 0 shares, with a net sale of 270,259 shares. During the past 18 months, 645,724 shares of Kiniksa Pharmaceuticals International PLC (KNSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 645,724 shares.
Kiniksa Pharmaceuticals International PLC (KNSA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kiniksa Pharmaceuticals International PLC Insider Transactions
Thomas Malley Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Malley. You might contact Thomas Malley via mailing address: C/o Kiniksa Pharmaceuticals, Ltd., Clarendon House, 2 Church Street, Hamilton D0 Hm11.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
